Company Overview
About Artiva Biotherapeutics
Artiva Biotherapeutics is a San Diego-based clinical-stage biotechnology company founded in 2019 with a mission to develop off-the-shelf, allogeneic natural killer (NK) cell therapies that can transform cancer treatment. NK cells are innate immune cells that can identify and kill cancer cells without requiring the patient-specific manufacturing that makes autologous CAR-T therapies so expensive and logistically complex. Artiva's allogeneic (donor-derived) approach enables manufacturing at scale from healthy donors, producing standardized cell therapy products that can be stored and shipped like conventional drugs.
Business Model & Competitive Advantage
Artiva completed its Nasdaq IPO in June 2024 under ticker symbol ARTV, following a Series C financing round of $150M. Total private funding prior to IPO exceeded $230M, from investors including GV (Google Ventures), Novo Holdings, Leaps by Bayer, and Foresite Capital. The company's lead program, AB-101, is an unmodified allogeneic NK cell therapy being evaluated in B-cell malignancies (blood cancers) and autoimmune diseases — including a clinical collaboration with Genentech targeting lupus. Artiva also has a CAR-NK platform (AB-201 and others) that adds chimeric antigen receptors to NK cells for enhanced tumor targeting.
Competitive Landscape 2025–2026
The NK cell therapy field has attracted significant investment as an alternative to CAR-T therapies, which require individualized manufacturing (4-6 weeks per patient) at costs exceeding $400K per treatment. Artiva's off-the-shelf model targets a much lower cost of goods and faster time to treatment, which is particularly important for hematologic malignancies where disease can progress rapidly. Competitor programs from Fate Therapeutics (acquired by Nkarta), Nkarta, and Cytovia are pursuing similar NK approaches, with Artiva distinguished by its autoimmune disease expansion strategy.
Key Differentiators
Emerging Innovator
Artiva Biotherapeutics is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Compare Artiva Biotherapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Start Comparison →Claim This Profile
Are you from Artiva Biotherapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Artiva Biotherapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Artiva Biotherapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →